Skip to main content

Table 4 Clinical characteristics and their prediction of overall survival in 127 HCC patients

From: Polymorphism in asparagine synthetase is associated with overall survival of hepatocellular carcinoma patients

Characteristics Number Survival Time, m mean (95%CI) P OR (95%CI)
Gender    0.68 1.12(0.65–1.93)
 male 107 39.1(35.1–43.2)   
 female 20 41.8(31.0–52.6)   
Smoking    0.24 0.72(0.41–1.25)
 No 86 40.8(36.1–45.4)   
 Yes 41 37.0(30.7–43.4)   
Drinking    0.90 1.04(0.57–1.89)
 No 97 40.3(36.0–44.6)   
 Yes 30 37.1(29.3–45.0)   
Family history of HCC    0.16 0.65(0.36–1.19)
 No 114 40.6(36.7–44.6)   
 Yes 13 30.2(18.0–42.4)   
rs1049674    0.829 0.80(0.10–6.17)
 TT 1 54.2   
 TA 22 33.6(24.0–43.2)   
 AA 104 40.7(36.6–44.8)   
rs34050735    0.001 7.21(2.30–22.6)
 TT 4 15.2(−2.4–32.7)   
 TG 35 34.4(27.7–41.1)   
 GG 88 42.7(38.2–47.2)   
Vascular invasion    0.51 0.86(0.55–1.34)
 No 78 39.2(34.4–44.1)   
 Yes 49 40.1(34.1–46.0)   
Differentiation    0.28 1.27(0.82–1.97)
 I + II 65 38.9(33.4–44.4)   
 III + IV 62 40.3(35.1–45.4)   
TNM stage    0.53 0.88(0.60–1.30)
 I + II 75 39.6(34.8–44.5)   
 III + IV 52 39.4(33.4–45.5)